| Literature DB >> 29599928 |
Liang Tang1,2, Jianming Li1,3, Huaiqing Luo1,2, Meihua Bao1,2, Ju Xiang1,2, Yiwei Chen1,2, Yan Wang1,2,4.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease. Relationships of 5HT2A and 5HTTLPR polymorphisms and AD risk have been widely investigated previously, whereas results derived from these studies were inconclusive and controversial. The aim of this study was to investigate the association of the 5-HT2A and 5HTTLPR polymorphisms and AD using a meta-analysis of existing literatures. Studies were collected using PubMed, Web of Science, the Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) and Embase. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess associations. As a result, a total of 7 publications for 5-HT2A T102C and 16 publications for 5HTTLPR (L/S) comprised 3255 cases and 3690 controls fulfilled the inclusion criteria. Significant association was covered between allelic and recessive models of 5-HT2A T102C and AD (allelic model: p = 0.003, OR [95% CI] = 1.23 [1.07, 1.40]; recessive model: p = 0.03, OR [95% CI] = 1.28 [1.02, 1.59]). Subsequently, we conducted subgroup analysis for 5-HT2A T102C polymorphism based on ethnicities and APOE ε4, and identified a significantly increased risk for the allelic and dominant models of 5-HT2A T102C and AD in Asian subgroup (allelic model: p = 0.002, OR [95% CI] = 1.42 [1.14, 1.78]; dominant model: p = 0.02, OR [95% CI] = 1.60 [1.09, 2.35]) and subgroup without APOE ε4 (allelic model: p = 0.02, OR [95% CI] = 1.44 [1.05, 1.99]; dominant model: p = 0.0008, OR [95% CI] = 2.49 [1.46, 4.25]). Nevertheless, the pooled analyses suggested no significant association between allelic, dominant, and recessive models of 5HTTLPR (L/S) and AD (p > 0.05). In conclusion, our meta-analysis demonstrates that 5HT2A C10T, but not 5HTTLPR (L/S), might increase risk for AD.Entities:
Keywords: 5-hydroxytryptophan 2A Receptor (5HT2A); Alzheimer’s disease (AD); Apolipoprotein E (APOE); meta-analysis; serotonin transporter (5HTT)
Year: 2017 PMID: 29599928 PMCID: PMC5871099 DOI: 10.18632/oncotarget.23611
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1PRISMA flow chart of studies inclusion and exclusion
Characteristics of eligible studies included in the meta-analysis
| Gene | Author (year) | Ethnicity | Number of cases | Number of controls | Age(case/control) | M/F(case: control) | source | result | HWE | Quality Assessment (NOS) |
|---|---|---|---|---|---|---|---|---|---|---|
| 5HT2A C102T | Lam et al. 2004 | Chinese | 87 | 75 | 77.4 ± 6.6/73.9 ± 5.6 | NA | HB | > 0.05 | > 0.05 | 7 |
| Rocchi et al. 2003 | Itailan | 135 | 90 | 72.4 ± 7.8/70.2 ± 9.1 | 45/90:30/60 | HB | > 0.05 | > 0.05 | 9 | |
| Micheli et al. 2006 | Itailan | 208 | 116 | 71.8 ± 9.5/70.8 ± 4.6 | 76/132:58/58 | PB | > 0.05 | > 0.05 | 9 | |
| Nacmias et al. 2001 | Itailan | 83 | 72 | 65.4 ± 8.4/74.5 ± 25.1 | NA | HB | > 0.05 | > 0.05 | 8 | |
| Ueno et al. 2007 | Japanese | 164 | 164 | 73.1 ± 8.3/73.0 ± 9.5 | 52/112:68/96 | HB | <0.05 | > 0.05 | 9 | |
| Zhang et al. 1999 | Chinese | 82 | 97 | 75 ± 8/70 ± 7 | NA | HB | > 0.05 | > 0.05 | 7 | |
| Fehér et al.2013 | Hungarian | 252 | 234 | 75.2 ± 7.4/74.6 ± 6.9 | 118/134:110/124 | HB | <0.05 | > 0.05 | 9 | |
| 5HTTLPR L/S | Kunugi et al. 2000 | Japanese | 123 | 326 | 79 ± 6/57 ± 8 | 35/88:151/185 | NA | > 0.05 | > 0.05 | 7 |
| Ha et al 2004 | Korean | 65 | 43 | 74.9 ± 6.9/73.1 ± 3.8 | 27/38:20/41 | HB | > 0.05 | > 0.05 | 9 | |
| Tsai et al.2001 | Chinese | 136 | 175 | 72.6 ± 5.3/71.5 ± 6.4 | 76/60:75/102 | HB | > 0.05 | > 0.05 | 9 | |
| Ueki et al. 2007 | Japanese | 200 | 200 | 73.3 ± 7.9/ 72.6 ± 8.8 | 66/134:7/127 | HB | > 0.05 | > 0.05 | 9 | |
| Fehér et al.2013 | Hungarian | 252 | 234 | 75.2 ± 7.4/74.6 ± 6.9 | 118/134:110/124 | HB | > 0.05 | > 0.05 | 9 | |
| Lorenzi et al. 2010 | Itailan | 218 | 54 | 75.49 ± 8.28/66.79 ± 6.99 | 77/141:28/26 | HB | <0.05 | > 0.05 | 9 | |
| Forero et al. 2006 | Colombian | 106 | 97 | 73.3 ± 8.8/72.2 ± 8.7 | NA | HB | > 0.05 | > 0.05 | 7 | |
| Gru¨nblatt et al. 2009 | Austrian | 127 | 479 | NA | 49/78:198/281 | HB | > 0.05 | > 0.05 | 9 | |
| Hu et al. 2000 | Germany | 50 | 99 | NA | NA | HB | > 0.05 | > 0.05 | 7 | |
| Li et al. 1997 | British | 196 | 257 | 82.5 ± 6.7/70.4 ± 8.5 | NA | HB | <0.05 | > 0.05 | 8 | |
| Oliveira et al. 1998 | Brazil | 81 | 244 | 70.02 ± 8.13/75.6 ± 10.2 | NA | NA | <0.05 | > 0.05 | 7 | |
| Polito et al. 2011 | Itailan | 235 | 207 | 78.6 ± 9.8/ 77.0 ± 9.3 | 74:161:69:138 | HB | <0.05 | > 0.05 | 9 | |
| Seripa et al. 2008 | Itailan | 105 | 114 | 78.42 ± 7.46/78.42 ± 7.46 | 34/71:69/45 | PB | > 0.05 | > 0.05 | 9 | |
| Sukonick et al. 2001 | American | 58 | 79 | 79.0 ± 8.0/73.1 ± 8.0 | 26/32:29/50 | HB | <0.05 | > 0.05 | 9 | |
| Zill et al. 2000 | Germany | 84 | 118 | 73 ± 9/47 ± 12 | 36/48:55/63 | NA | > 0.05 | > 0.05 | 8 | |
| Micheli et al. 2006 | Itailan | 208 | 116 | 71.8 ± 9.5/70.8 ± 4.6 | 76/132:58/58 | PB | > 0.05 | > 0.05 | 9 |
Abbreviations: 5HT2A: 5-hydroxytryptophan 2A Receptor; 5HTTLPR: 5HTT gene-linked polymorphic region; L: long; S:short; M: male; F; female; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; NOS: Newcastle-Ottawa Scale.
The association between 5HT2A C102T and Alzheimer’s disease
| SNPs | Genetic Model | Number of studies | Numbers | Test of association | Model | Test of heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| case | control | OR[95% CI] | I2 (%) | ||||||
| 5HT2A (C) | Allelic(C) | ||||||||
| total | 7 | 1863 | 1666 | 1.23 [1.07, 1.40] | 0.003 | F | 0.10 | 44 | |
| Asian | 3 | 599 | 642 | 1.42 [1.14, 1.78] | 0.002 | R | 0.05 | 66 | |
| Caucasian | 4 | 1264 | 1024 | 1.13 [0.95, 1.33] | 0.16 | F | 0.54 | 0 | |
| With APOE ε4 | 2 | 256 | 102 | 0.98 [0.28, 3.38] | 0.94 | R | 0.01 | 84 | |
| Without APOE ε4 | 2 | 236 | 420 | 1.44 [1.05, 1.99] | 0.02 | F | 0.75 | 0 | |
| Dominant(CC+CT/TT) | |||||||||
| total | 6 | 878 | 773 | 1.23 [0.97, 1.54] | 0.08 | F | 0.23 | 28 | |
| Asian | 2 | 246 | 261 | 1.60 [1.09, 2.35] | 0.02 | F | 0.20 | 38 | |
| Caucasian | 4 | 632 | 512 | 1.05 [0.79, 1.40] | 0.72 | F | 0.49 | 0 | |
| With APOE ε4 | 2 | 128 | 51 | 0.73 [0.35, 1.52] | 0.39 | F | 0.17 | 48 | |
| Without APOE ε4 | 2 | 118 | 210 | 2.49 [1.46, 4.25] | 0.0008 | F | 0.79 | 0 | |
| Recessive(CC/CT+TT) | |||||||||
| total | 6 | 878 | 773 | 1.28 [1.02, 1.59] | 0.03 | F | 0.42 | 0 | |
| Asian | 2 | 246 | 261 | 1.24 [0.81, 1.88] | 0.32 | R | 0.05 | 74 | |
| Caucasian | 4 | 632 | 512 | 1.29 [0.99, 1.68] | 0.06 | F | 0.76 | 0 | |
| With APOE ε4 | 2 | 128 | 51 | 1.84 [0.11, 29.95] | 0.67 | R | 0.009 | 85 | |
| Without APOE ε4 | 2 | 118 | 210 | 1.01 [0.59, 1.73] | 0.98 | F | 0.42 | 0 | |
Abbreviations: 5HT2A: 5-hydroxytryptophan 2A Receptor; APOE; Apolipoprotein E; R: random model; F: fixed model; OR: odds ratios; CIs: confidence intervals.
Figure 2Forest plots of odds ratios for the association between 5HT2A C102T and AD
(A) Allelic model; (B) Dominant model; (C) Recessive model.
The association between 5HTTLPR and Alzheimer’s disease
| SNPs | Genetic Model | Number of studies | Numbers | Test of association | Model | Test of heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| case | control | OR [95% CI] | I2 (%) | ||||||
| 5HTTLPR (L) | Allelic(L) | ||||||||
| total | 16 | 4350 | 5764 | 1.10 [0.76, 1.60] | 0.62 | R | < 0.00001 | 94 | |
| Asian | 4 | 1048 | 1388 | 0.93 [0.66, 1.31] | 0.67 | R | 0.06 | 60 | |
| Caucasian | 12 | 3302 | 4376 | 1.16 [0.72, 1.85] | 0.54 | R | < 0.00001 | 96 | |
| With APOE ε4 | 5 | 628 | 330 | 1.31 [0.69, 2.48] | 0.41 | R | 0.02 | 65 | |
| Without APOE ε4 | 5 | 756 | 1188 | 1.50 [0.87, 2.59] | 0.61 | F | 0.18 | 36 | |
| Dominant(LL+LS/SS) | |||||||||
| total | 14 | 1884 | 2399 | 1.02 [0.81, 1.27] | 0.88 | R | 0.01 | 53 | |
| Asian | 4 | 524 | 744 | 1.09 [0.84, 1.40] | 0.52 | F | 0.92 | 0 | |
| Caucasian | 10 | 1360 | 1655 | 1.01 [0.73, 1.40] | 0.96 | R | 0.002 | 66 | |
| With APOE ε4 | 5 | 332 | 165 | 1.42 [0.86, 2.34] | 0.17 | F | 0.36 | 9 | |
| Without APOE ε4 | 5 | 378 | 594 | 0.94 [0.58, 1.52] | 0.81 | R | 0.05 | 58 | |
| Recessive(LL/LS+SS) | |||||||||
| total | 15 | 2098 | 2453 | 0.87 [0.65, 1.17] | 0.36 | R | < 0.0001 | 70 | |
| Asian | 4 | 524 | 744 | 1.10 [0.68, 1.78] | 0.69 | F | 0.88 | 0 | |
| Caucasian | 11 | 1574 | 1709 | 0.83 [0.59, 1.17] | 0.29 | R | < 0.00001 | 78 | |
| With APOE ε4 | 5 | 332 | 164 | 0.65 [0.36, 1.18] | 0.16 | F | 0.78 | 0 | |
| Without APOE ε4 | 5 | 378 | 594 | 0.91 [0.64, 1.30] | 0.60 | F | 0.30 | 18 | |
Abbreviations: 5HTTLPR: 5HTT gene-linked polymorphic region; L: long; S:short; APOE; Apolipoprotein E; R: random model; F: fixed model; OR: odds ratios; CIs: confidence intervals.
Figure 3Forest plots of odds ratios for the association between 5HTTLPR (L/S) and AD
(A) Allelic model; (B) Dominant model; (C) Recessive model.
Figure 4Sensitivity analyses between allelic models of 5HT2A C102T and 5HTTLPR (L/S) and AD
(A) 5HT2A C102T; (B) 5HTTLPR (L/S).
Figure 5Publication biases of literatures for 5HT2A C102T and 5HTTLPR (L/S) were tested by Begg’s funnel plot and Egger’s test
(A) 5HT2A C102T; (B) 5HTTLPR (L/S).